BIOLOGIAL RESPONSE MODIFIERS AS THERAPIES FOR AIDS

生物反应调节剂作为艾滋病疗法

• 批准号: 2296956
• 负责人: JULIE L. EISEMAN
• 金额: $ 3.8万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-09-01 至 1992-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2296956
• 关键词: BIOLOGIAL; RESPONSE; MODIFIERS; THERAPIES; AIDS

The objective of this contract is to facilitate the entry of biological response modifiers (BRMs) into clinical trials. This will be accomplished by examining the potential efficacy of BRMs in an appropriate retrovirus infected animal model. Efforts will be made to evaluate BRMs alone or in combination with other drugs in an appropriate animal/retrovirus model to determine their potential usefulness as a therapy for AIDS. BRMs are agents or methods used to alter the host's biological response to infection with a resultant therapeutic effect. BRMs may function in several ways. Some increase the host's antiviral responses by augmenting or restoring the effector arms directly or indirectly. Others may function to increase the growth and differentiation of lymphocytes or macrophages thus increasing the ability of the host to tolerate damage by cytotoxic drugs that may be used in the treatment of AIDS. Cytokines, lymphokines, monokines, growth factors, tumor necrosis factors and inducers of these proteins are examples of some of the BRMs known to date. The Division of Cancer Treatment (DCT) of the National Cancer Institute has ben developing these agents in the treatment of tumors. Until recently little work has been done to develop the use of BRMs alone or in combination with other drugs for the treatment of viral infections. It may be that therapies for AIDS which require long term treatment with an antiviral agent (e.g. nucleoside analogue) may require combination therapy with a modualtor of the immune response. BRMs could be used to decrease the toxicity of the drug by increasing the number of lymphocytes or aid in the immune response against this viral infection. At present, research into this area needs to be increased. It is the purpose of this solicitation to develop the use of BRMs for AIDS therapy. This will be accomplished by evaluation BRMs alone or in combination with other drugs in an retrovirusanimal model which mimics the disease AIDS.

该合同的目的是促进 生物反应修饰剂（BRMS）进入临床试验。 这会 可以通过检查BRM的潜在功效来实现 适当的逆转录病毒感染动物模型。 努力将是 为单独评估BRM或与其他药物结合而制作 在适当的动物/逆转录病毒模型中以确定其 作为艾滋病治疗的潜在有用性。 BRM是代理商或 用于改变宿主对感染的生物反应的方法 产生的治疗作用。 BRM可能在 几种方式。 有些人通过 直接或间接增加或恢复效应器臂。 其他人可能会提高增长和差异 淋巴细胞或巨噬细胞，从而提高了 宿主可以通过细胞毒性药物耐受损害 艾滋病的处理。 细胞因子，淋巴因子，Monokines， 生长因子，肿瘤坏死因子和诱导剂 蛋白质是迄今已知的一些BRM的例子。 这 国家癌症的癌症治疗部（DCT） 研究所让本·贝（Ben）开发这些代理人 肿瘤。 直到最近，几乎没有做过开发的工作 单独使用BRM或与其他药物结合使用 病毒感染的治疗。 可能是艾滋病的疗法 需要长期用抗病毒剂治疗（例如 核苷类似物）可能需要与 免疫反应的模量。 BRM可以用来 通过增加数量来降低药物的毒性 淋巴细胞或帮助对此病毒的免疫反应 感染。 目前，对该领域的研究必须是 增加。 这是这种征集的目的 BRMS的艾滋病治疗。 这将通过 单独评估BRM或与其他药物合并 逆转录病毒模型，模拟疾病有助于疾病。